Ankylosing Spondylitis
📧 Sign up to get email alerts when something new happens for Ankylosing Spondylitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
A completed two-year real-world study assessing retention, quality of life, effectiveness and treatment patterns of secukinumab in adults wi…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
A ClinicalTrials.gov update describes a biospecimen collection study led by TScan Therapeutics to identify targets of disease-reactive T cel…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of LNK01001 in adults with ankylosing spondylitis is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Whole Body MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Radiographic axSpA and Non-radiographic axSpA
This clinical trial is recruiting to assess whole-body MRI for non-invasive lesion detection and therapy follow-up in patients with axial sp…
-
EMA approval · 2025-11-10EMA Authorised: Flixabi (infliximab) — Samsung Bioepis NL B.V.
The EMA authorised Flixabi, a biosimilar of infliximab, for several inflammatory diseases. The indications include rheumatoid arthritis, pso…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
A clinical trial is evaluating an educational tool to help melanoma patients with pre-existing autoimmune diseases who are candidates for im…
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
EMA approval · 2025-10-21EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Idacio, a biosimilar of adalimumab, for multiple inflammatory diseases, produced by Fresenius Kabi Deutschland GmbH. The indi…
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity [NA]
This document provides an update on a rheumatology-focused clinical trial sponsored by Brigham and Women's Hospital that studies an adaptive…
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
FDA approval · 2025-10-03FDA Approved: NAPROXEN — Original Application (Aurobindo Pharma Limited)
FDA approved Naproxen from Aurobindo Pharma Limited as an original generic application (ANDA 216504). Naproxen is a nonsteroidal anti-inflam…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
A clinical trial from Peking University People's Hospital evaluating mass spectrometry-based immune profiling across autoimmune diseases; th…
-
FDA approval · 2025-09-17FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental BLA for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited. The action concerns regulatory approval rel…
-
CLINICAL_TRIALS research · 2025-09-12Clinical Trial Update: Mediterranean Diet and Disease Activity in Axial Spondyloarthritis Receiving Biologic Therapy [NA]
A clinical trial evaluating whether a Mediterranean diet affects disease activity in axial spondyloarthritis patients on biologic therapy; t…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis [NA]
A clinical trial is investigating the impact of a gluten-free diet on symptoms and disease activity in people with ankylosing spondylitis. T…
-
FDA approval · 2025-09-03FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Inflectra (infliximab-dyyb) from Pfizer to update its labeling and/or indications, following…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: Telerehabilitation and Face-to-Face Clinical Pilates-Based Exercise in Individuals With Axial Spondyloarthritis [NA]
A completed clinical trial comparing telerehabilitation and face-to-face clinical Pilates-based exercise in individuals with axial spondyloa…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: The Effect of Laughter Yoga on Patients With Ankylosing Spondylitis [NA]
A clinical trial is evaluating the effect of laughter yoga on patients with Ankylosing Spondylitis, with recruitment not yet started.
-
EMA approval · 2025-08-13EMA Authorised: Enbrel (etanercept) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Enbrel (etanercept) for multiple inflammatory diseases including rheumatoid arthritis, ankylosing s…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: The Relationship Between Arterial Stiffness and Pulmonary and Extrapulmonary Features in Ankylosing Spondylitis
This clinical trial update reports ongoing recruitment for a study investigating the relationship between arterial stiffness and pulmonary a…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Characteristics of Ankylosing Spondylitis Associated Uveitis
A completed clinical trial update describing the characteristics of uveitis in patients with ankylosing spondylitis.
-
FDA approval · 2025-07-29FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Sandoz Inc for the adalimumab biosimilar ADALIMUMAB-ADAZ, enabling its use with indications cons…